Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | The importance of reimbursement and accessibility for CTCs and cfDNA testing

Stefanie Zschaebitz • 1 Jun 2025
ASCO 2025
Genitourinary Cancer Prostate Cancer

Stefanie Zschaebitz, Heidelberg University Hospital, Heidelberg, Germany, emphasizes the importance of reimbursement and accessibility for circulating tumor cells (CTCs) and cell-free DNA (cfDNA) testing, particularly for community practitioners, highlighting that ease of sample collection and submission is crucial for widespread adoption. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Stefanie Zschaebitz

Reimbursement for targeted therapy: a challenge for community practitioners
1:05
Reimbursement for targeted therapy: a challenge for community practitioners
Stefanie Zschaebitz • 1 Jun 2025
The use of ctDNA in prostate cancer diagnosis and treatment
0:42
The use of ctDNA in prostate cancer diagnosis and treatment
Stefanie Zschaebitz • 2 Jun 2025
Integrating genomic biomarkers into prostate cancer treatment selection
0:53
Integrating genomic biomarkers into prostate cancer treatment selection
Stefanie Zschaebitz • 2 Jun 2025
Enhancing our understanding of HRR gene defects in prostate cancer
0:37
Enhancing our understanding of HRR gene defects in prostate cancer
Stefanie Zschaebitz • 2 Jun 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals